ClinicalTrials.gg
RecruitingNCT06467825Lunar OIUpdated Apr 1, 2025

Effect of Sex on Orthostatic Intolerance and Cardiovascular Response During Lunar Descent and Ascent

An interventional study of Potassium Supplement and Furosemide 20 MG in Healthy, sponsored by National Aeronautics and Space Administration (NASA). Recruiting at 1 site in United States. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by National Aeronautics and Space Administration (NASA) · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 6 months after the study started (first participant enrolled Aug 2022, registered Mar 2024).
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
25 Years to 55 Years
Sex
All
01

Study summary

The purpose of Lunar OI (Orthostatic Intolerance) is to determine if there are differences between males and females in tolerance to and cardiovascular responses during different angles of head-up tilt simulating gravity levels less than or equal to Earth's gravity. Also, this study will determine if a gradient compression garment affects tolerance to tilting and the cardiovascular stress at different tilt angles. Males and females are being identified by biological sex. This will be a two-phased study design. In Phase I we will determine whether there are differences in the development of signs or symptoms of orthostatic intolerance between males and females when tilted head up on a table to different angles to simulate gravity levels that astronauts may experience when landing on or launching from the surface of the Moon. In Phase II, the tilt tests simulating the same gravity levels from Phase I will be repeated, but a custom-made lower-body compression garment will be worn to see if wearing the garment affects the development of orthostatic intolerance. For both study phases, before tilting, a drug will be administered to reduce the amount fluid in the blood (plasma) to levels similar to that experienced by astronauts during spaceflight.

Read the detailed description

Phase I, Visit one Alpha (1A);

OIG (Orthostatic Intolerance Garment) Measurement:

Participants will lie supine while torso and anthropometric measurements are acquired. The investigators will utilize the same procedures developed and adopted by the Orion Program to obtain foot, leg, and torso circumference measurements at pre-determined intervals. This detailed measurement procedure has shown to be effective at providing precise compression levels at pre-determined anatomical locations. The target levels of compression will be verified by the manufacturer, using a Hosiery and Allied Trades Research Association (HATRA) test instrument that is identified in the British Standard for testing compression in elastic stockings.

Tilt Familiarization:

Participants will be instructed to lie supine without moving throughout the Familiarization tilt test. After instrumentation with brachial blood pressure, continuous blood pressure monitoring, and electrocardiogram (ECG) for heart rate, baseline measures will be obtained for at least 2 minutes while the test is explained. Participants will be tilted to 80˚ head-up and instructed to remain still and quiet. After allowing the participant to become familiar with the tilt procedure and the feeling of being upright, the bed will be lowered back to horizontal (flat) and a timer started for a 20-minute supine rest period.

Plasma and Blood Volume Measurement:

An intravenous (IV) catheter will be inserted into a vein in the participant's arm or hand using standard techniques. All blood samples will be obtained using the IV catheter in the participant's arm, unless it becomes clogged, and another IV catheter cannot be placed in another arm or hand vein. In this situation, blood could be drawn from the participant's arm or hand vein using a butterfly needle.

Participants will be supine for 20 minutes before this test begins. A clip will be placed on the participant's nose so that they are breathing only through their mouth. Participants will breathe through a mouthpiece connected to a rebreathing circuit containing 100% oxygen, which is scrubbed by soda lime to remove carbon dioxide. After \~5 minutes, a \~10 mL blood sample will be collected using the IV catheter. Thereafter, a small amount of carbon monoxide will be added into the breathing circuit, and the participant will breathe this mixture of carbon monoxide and oxygen for \~10 min. Then, a second \~10 mL blood sample will be obtained. Analysis of the blood samples (i.e., hematocrit, hemoglobin, and carboxyhemoglobin) will be used to calculate red blood cell mass, plasma volume, and total blood volume.

Normovolemic Tilt Test at one unit of gravity (1G):

This test will be similar to the Tilt Familiarization session, but baseline data will be collected for \~5 minutes while supine. After tilting up, participants will remain quiet, relaxed, and not move for up to 20 minutes or until presyncope. Brachial blood pressure will be measured, and ultrasound images obtained to quantify stroke volume approximately every minute. Blood pressure and ECG will be continuously monitored before, during, and after the tilt. A tilt test will be terminated if any of the following test termination criteria are met: sudden drop in heart rate (>15 bpm), systolic blood pressure (>25 mmHg) or diastolic blood pressure (>15 mmHg); significant cardiac arrhythmias such as an ectopic rhythm >4 beats; absolute systolic blood pressure \<70 mmHg; symptoms such as nausea, clammy skin, profuse sweating, pallor, light-headedness, dizziness, or tingling; or participant request. In the event a tilt test is terminated prior to 20 minutes, the participant will be brought to a head-down tilt position until recovered.

Visit one Bravo (1B);

Plasma Volume + Furosemide Infusion:

Plasma volume will be measured as described in Phase 1A. After the plasma volume test is complete, a 20 mg of Furosemide will be administered intravenously. This dose has been demonstrated to produce plasma volume losses similar to spaceflight and bedrest. An oral potassium supplement of 20 mEq (Milliequivalent) will be given as a prophylactic prior to the furosemide infusion.

Induction of Hypovolemia:

Following Furosemide infusion, participants will remain in the CVL (Cardiovascular and Vision Laboratory) and be observed while remaining seated (except for bathroom trips) for 2 hours. During this time urine volume and periodic blood pressure will be obtained. Participants will self-collect urine using urine collection bottles and provide to the test operator to document the time of urine collection and volume produced. Participants will be given a standardized volume of water at intervals throughout the study day. Participants will be provided snacks as needed throughout the duration of their stay in the laboratory.

Hypovolemic Tilt Tests (1-G, 0.75-G, 0.50-G):

Following the 2-hour period for diuresis to develop, participants will undergo 3 tilt tests (80°, 50°, and 30° head-up tilt) for up to 20 minutes each to simulate 1-G, 0.75-G, and 0.50-G exposures. The tilt tests will occur in a random order and participants will remain supine for 20 minutes to fully recover between tests. The timing, monitoring, and test termination criteria will be identical to that described in Normovolemic Tilt Test (1G) above. Immediately prior to each tilt test, a blood sample (5 mL) will be drawn using the IV catheter and analyzed for hematocrit and hemoglobin concentration, which will then be used to calculate the change in plasma volume since the baseline test. Alternatively, if the IV becomes clogged and another IV cannot be placed, these blood samples could be drawn from an arm or hand vein using a butterfly needle (5 mL) or by pricking the finger (80 μL).

Phase II, Visit two Alpha (2A);

OIG Fit Check:

Participants will don their custom OIG garments to ensure there were no errors in garment development.

Visit two Bravo (2B):

Plasma Volume + Furosemide Infusion Participants will complete the same testing protocol as occurred in Phase 1B.

Induction of Hypovolemia:

Participants will complete the same testing protocol as occurred in Phase 1B.

Hypovolemic Tilt Tests (1-G, 0.75-G, 0.50-G) + OIG:

Following the 2-hour period for diuresis to develop, participants will don their custom-made OIG and assume the supine posture for \~20 minutes prior to starting the first tilt test. The order of the 3 tilt tests (80°, 50°, and 30° head-up tilt) will be the same order as occurred in Phase 1B, Hypovolemic Tilt Tests (1-g, 0.75-G, 0.50-G).

Visits 2A and 2B can be combined.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

National Aeronautics and Space Administration (NASA) is the lead sponsor of 14 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pass a test subject screening facility modified Air Force Class III physical

Exclusion criteria

Exclusion Criteria:

  • Known allergy to furosemide or sulfa drugs
  • Currently taking drugs or medications known to adversely interact with furosemide, including but not limited to aspirin, NSAIDs, antibiotics, or drugs
  • Systemic diseases or current medications known to influence the cardiovascular system
  • Renal disease
  • Type II Diabetes
  • Pregnant participants will be excluded (a urine pregnancy screen will be made available).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • No intervention
    Control
  • Experimental
    Hypovolemic

    Furosemide and potassium supplement.

    Drug: Potassium Supplement · Drug: Furosemide 20 MG

  • Experimental
    Hypovolemic plus garment

    Furosemide and potassium supplement plus OIG.

    Drug: Potassium Supplement · Drug: Furosemide 20 MG · Device: Compression Garment

Interventions

  • DrugPotassium Supplement

    Participants will be given a potassium supplement that will help prevent low blood potassium levels.

  • DrugFurosemideStudies of FurosemideFurosemide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Furosemide (Lasix, 20 mg) will be administered through IV catheter to induce urination. The goal of this procedure is to reduce the volume of plasma in the blood.

    Also known as: Lasix

  • DeviceCompression Garment

    From the torso and leg measurements obtained during Visit 1A, a custom-designed compression garment will be constructed.

06

What researchers measure

Primary outcomes

  1. Plasma Volume

    Plasma volume and change in plasma volume is calculated using the Dill and Costill equation cited here: Dill DB, Costill DL. Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration.

    Time frame: 7-8 hours

  2. Tilt Tolerance Time

    duration of Tilt Test

    Time frame: 0-20 minutes

  3. Heart Rate

    beats per minute

    Time frame: 0-20 minutes

  4. Blood Pressure

    systolic and diastolic, continuous blood pressure

    Time frame: 0-20 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Sep 2025, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2024
First posted
Jun 21, 2024
StartActual
Aug 9, 2022
Primary completionEst.
Sep 2025
CompletionEst.
Sep 2025
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06467825
Lead sponsor
National Aeronautics and Space Administration (NASA)
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Aug 9, 2022
Primary completion
Sep 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Apr 1, 2025

Study contacts

Jason R Lytle, PhD
Contact
jsc-cardilab@mail.nasa.gov
281-483-9531
Lucinda M Yu, MS
Contact
jsc-cardilab@mail.nasa.gov

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Furosemide

Start the discussion